iOmx Therapeutics

iOmx Therapeutics is a biopharmaceutical company focused on developing first-class cancer immunotherapies that address novel immune checkpoints hijacked by cancer cells. Using the iOTargTM high-throughput screening platform, iOmx has identified several next-generation immune checkpoints associated with tumors and is advancing the development of promising preclinical candidate drugs that have the potential to address cancers resistant to existing immunotherapies. The company’s lead project, IMT-07, targets SIK3, an immune-protective kinase for various solid tumors, while IMT-18 is a first-in-class antibody designed to inhibit IGSF11, an immune checkpoint for PD-1/PD-L1-resistant tumors.